Mission Pharmacal Header

Mission Pharmacal Header

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Filters

×

FILTER:

filter

News Type

filter

Company

filter

Product Type

filter

Deal Size

filter

Upfront Payment

Active Filter(s):

Filters

Reset Filter

All Developments

Product Type

Companies

[{"company":"Eleusis","sponsor":"Not Applicable ","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Eleusis Announces Long Lasting Antidepressant-Like Effects of Psychedelics When Compared to Ketamine in Animals","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"March 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Eleusis"},{"company":"Nuformix","sponsor":"VistaGen Therapeutics","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"VistaGen and Nuformix agree to develop cocrystalline forms of AV-101","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2020","url1":"","url2":"","graph1":"Small molecule","graph2":"Nuformix"},{"company":"Compass Pathways","sponsor":"MiHKAL GmbH","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs","therapeuticArea":"Psychiatry\/Psychology","highestDevelopmentStatus":"Preclinical","country":"UNITED KINGDOM","productType":"Small molecule","productStatus":"New Molecular Entity","date":"September 2021","url1":"","url2":"","graph1":"Small molecule","graph2":"Compass Pathways"}]

Compass Pathways

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

COMPASS Pathways acquires IP portfolio of novel psychedelic compounds and prodrugs

Details:

The substances covered in the IP portfolio include a variety of psychedelic and empathogenic compounds, some of which are prodrugs - pharmacologically inactive compounds which are metabolised inside the body to produce an active drug.

Lead Product(s): Psychedelic Compound

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: MiHKAL GmbH

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition September 14, 2021

ASK
US

Upload
your Pipeline Activity

Nuformix

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

VistaGen and Nuformix agree to develop cocrystalline forms of AV-101

Details:

Under this agreement, VistaGen and Nuformix initially will apply Nuformix's proprietary technology platform to develop patentable new crystalline forms of AV-101 that may have superior delivery, an enhanced therapeutic profile and additional intellectual property protection.

Lead Product(s): 4-Chlorokynurenine,Probenecid

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: VistaGen Therapeutics

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement May 27, 2020

ASK
US

Upload
your Pipeline Activity

Eleusis

Contact Supplier

Upload your Marketing & Sales content on your company Virtual Booth, click HERE

Post an Enquiry

Post an Enquiry

Digital Content

Eleusis Announces Long Lasting Antidepressant-Like Effects of Psychedelics When Compared to Ketamine in Animals

Details:

The research reveals that both psilocybin and lysergic acid diethylamide (LSD) significantly reduce depressive-like behaviors five weeks after a single administration.

Lead Product(s): Psilocybine,LSD

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Preclinical Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 05, 2020

ASK
US

Upload
your Pipeline Activity

POST ENQUIRY